免疫疗法采用天然分子而非主要桃过敏原普鲁兰肽 p 3 的低变应原性变体，在小鼠中显示出有益效果。
Immunotherapy with Native Molecule rather than Hypoallergenic Variant of Pru p 3, the Major Peach Allergen, Shows Beneficial Effects in Mice.
机构信息
Research Laboratory, IBIMA-Hospital Regional Universitario de Malaga-UMA, Pabellón 5 Sótano, 29009 Malaga, Spain.
Molecular Allergology, Paul-Ehrlich-Institut, Paul Ehrlich Street 51-59, 63225 Langen, Germany.
出版信息
J Immunol Res. 2018 Jun 13;2018:3479185. doi: 10.1155/2018/3479185. eCollection 2018.
BACKGROUND
The use of hypoallergenic derivatives is considered beneficial to promote the safety and efficacy of allergen-specific immunotherapy. We aimed to assess the efficacy of reduced and alkylated (R/A) Pru p 3, a hypoallergenic folding variant of the major peach allergen, in subcutaneous immunotherapy (SCIT) using a murine model of peach allergy.
METHODS AND RESULTS
After sensitization with Pru p 3, BALB/c mice received SCIT with Pru p 3 or R/A Pru p 3 and were challenged with Pru p 3. SCIT with Pru p 3, but not with R/A Pru p 3, suppressed anaphylaxis upon the challenge significantly. SCIT with Pru p 3 did not suppress Pru p 3-specific IgE and IgG1 production, but enhanced IgG2a production. In contrast, SCIT with R/A Pru p 3 suppressed IgE and IgG1 production, but enhanced IgG2a production only moderately. The therapeutic efficacy of SCIT with Pru p 3 was associated with induction of IL-10 and IFN-.
CONCLUSION
Hypoallergenic folding variant of Pru p 3 is not likely an efficacious therapeutic component in SCIT of peach allergy. The lower efficacy of R/A Pru p 3 might be attributed to poor antigenicity and/or weak stability due to its unfolded conformation.
背景
使用低变应原性衍生物被认为有利于提高过敏原特异性免疫治疗的安全性和疗效。我们旨在评估低变应原性折叠变体普鲁 3（R/A Pru p 3）在桃过敏皮下免疫治疗（SCIT）中的疗效，该变体是主要桃过敏原的变应原性衍生。
方法和结果
在致敏 Pru p 3 后，BALB/c 小鼠接受 Pru p 3 或 R/A Pru p 3 的 SCIT，并接受 Pru p 3 挑战。SCIT 用 Pru p 3，但不是 R/A Pru p 3，显著抑制了过敏反应。SCIT 用 Pru p 3 不会抑制 Pru p 3 特异性 IgE 和 IgG1 的产生，但增强了 IgG2a 的产生。相比之下，SCIT 用 R/A Pru p 3 抑制 IgE 和 IgG1 的产生，但仅适度增强 IgG2a 的产生。SCIT 用 Pru p 3 的治疗效果与诱导 IL-10 和 IFN-有关。
结论
Pru p 3 的低变应原性折叠变体不太可能成为桃过敏 SCIT 的有效治疗成分。R/A Pru p 3 的低疗效可能归因于其未折叠构象导致的抗原性差和/或稳定性弱。
Zotero 插件